RxDoctor Payments Data

Kenneth D'souza, MD

Pulmonary Disease · Cincinnati, OHNPI 1366896680

Payments from drug & device makers

$8,633in general payments, 2019–2025

Across 67 payments — averaging $128.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Atricure, Inc.$299
  • Boehringer Ingelheim$249
  • Inari Medical, Inc.$192
  • Sanofi$163
  • E.r. Squibb & Sons, L.L.C.$126
  • plus $895 from 19 others

What the payments were for

  • Travel & lodging$5857%
  • Food & beverage$2,04824%
  • Education$6,00069%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,633 in reported general payments places this provider in the 70th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$110,882
Medicare patients
380
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$87,959
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr115$60,104
Dupixent PenDupilumab12$43,168
Breo ElliptaFluticasone/Vilanterol51$25,011
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$19,671
SymbicortBudesonide/Formoterol Fumarate56$17,539
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$16,499
Incruse ElliptaUmeclidinium Bromide18$9,015
Combivent RespimatIpratropium/Albuterol Sulfate17$8,143
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,634
Varenicline Tartrate18$5,085
Fluticasone-SalmeterolFluticasone Propion/Salmeterol43$4,926
Albuterol Sulfate HfaAlbuterol Sulfate150$4,678
DuleraMometasone/Formoterol11$4,187
Arnuity ElliptaFluticasone Furoate16$4,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$70$186,273310 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$70$42,84596 claims
Boehringer IngelheimStiolto Respimat, Combivent Respimat$249$24,64345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →